article · IDOSR JOURNAL OF EXPERIMENTAL SCIENCES
Pseudomonas aeruginosa is a ubiquitous bacterium that causes various hospital- acquired and community-acquired infections. It has been reported that the clinical isolates of P. aeruginosa are difficult to treat because of their virulence factors and antibiotics resistances. The aim of present study was to screen the antibiotic resistance patterns and the prevalence of virulence factor genes in a set of Pseudomonas aeruginosa isolated from Ogbomoso, and to determine whether a correlation exists between the prevalence of virulence factors and antibiotic resistance of P. aeruginosa. A total of 100 P. aeruginosa isolates were collected from various types of clinical specimens. Antimicrobial susceptibility testing was performed using the Kirby-bauer method. In addition, PCR assays were used for screening four virulence encoding genes (OPRL, LasB, PLCH and ToxA). The results showed that OPRL (79%) and LasB (62%) were the most frequent virulence genes in P. aeruginosa strains, followed by PLCH (41%) and ToxA (35%). The highest resistance was detected towards Piperacillin (42%) and Tetracycline (42%). Moderate rate of resistance (12-39%) were detected towards the other antibiotics. The virulent factors identified in this study provide valuable information regarding the prevalence of resistance genes of P. aeruginosa isolates in Ogbomoso, Nigeria and their potential impact on treatments that exploit the unique physiology of the pathogen. This will be useful for the health workers to improve infection control measures and to establish a surveillance system. Keywords: antibiotic resistance, virulence genes, Pseudomonas Aeruginosa
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.59298/idosr/jes/101.1.7009
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.